Supernus Pharmaceuticals, Inc. will announce its second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. The biopharmaceutical company, focused on developing and commercializing products for central nervous system (CNS) diseases, scheduled the disclosure to provide investors with an update on its operational performance.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast at 4:30 p.m. ET on August 4, 2026, to discuss these results. The session will include management’s prepared remarks followed by a question-and-answer period for analysts and investors.

Investors can access the live webcast through the Events & Presentations section of the company’s Investor Relations website at www.supernus.com/investors . Participants wishing to join via phone may pre-register at any time before the call to receive a personalized dial-in number and conference code. The company recommends dialing in 15 minutes prior to the start time.

A replay of the webcast will be available on the company’s Investor Relations website for 60 days following the live call. This extended availability ensures stakeholders can review the discussion and financial details at their convenience.

Supernus Pharmaceuticals’ portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease patients, hypomobility in Parkinson’s disease, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company continues to develop novel product candidates for CNS disorders.

Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Supernus Pharmaceuticals and raised the price target to $67 from $63. The adjustment reflects a revised outlook on the company's stock performance. Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol SUPN.